bioAffinity Technologies (BIAF) Cash from Operations (2021 - 2026)

bioAffinity Technologies has disclosed Cash from Operations across 6 years of filings, most recently posting 3227240.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 96.57% year-over-year to 3227240.0; the TTM figure through Mar 2026 stood at 10914307.0 (down 66.36% YoY), while the FY2025 annual figure was 9328842.0, down 28.41% from the prior year.
• Cash from Operations slipped to 3227240.0 in Q1 2026, from 2559563.0 in the prior quarter.
• Over the last five years, Cash from Operations for BIAF reached as high as 376141.0 in Q2 2022 and fell as low as 3227240.0 in Q1 2026.
• The 5-year median for Cash from Operations is 1641775.0 (2025), against an average of 1760560.47.
• Annual changes were most pronounced in 2023 — Cash from Operations slumped 261.55% — and 2025, when it jumped 30.02%.
• A 5-year view of Cash from Operations shows it stood at 1300636.0 in 2022, then slipped by 24.27% to 1616303.0 in 2023, then decreased by 3.77% to 1677161.0 in 2024, then sank by 52.61% to 2559563.0 in 2025, then declined by 26.09% to 3227240.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 3227240.0, 2559563.0, and 2480298.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.